Barclays Maintains Overweight on Arcus Biosciences, Lowers Price Target to $35
Barclays analyst Peter Lawson maintains Arcus Biosciences (NYSE:RCUS) with a Overweight and lowers the price target from $60 to $35.
12 Health Care Stocks Moving In Tuesday’s Intraday Session
Gainers Athenex (NASDAQ:ATNX) stock moved upwards by 41.4% to $0.19 during Tuesday’s regular session. Trading volume for this…
Gilead Sciences Announces Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared To Anti-PD1 Alone In Phase 2 Non-Small Cell Lung Cancer Study
Gilead Sciences, Inc. (NASDAQ:GILD) and Arcus Biosciences, Inc. (NYSE:RCUS) today announced positive results from the fourth interim analysis of the ARC-7 study in patients with first-line, metastatic non-small cell lung
Gilead-Arcus Biosciences Partnered Lung Cancer Therapy Shows Continuous Positive Efficacy Measures
Gilead Sciences Inc (NASDAQ:GILD) and Arcus Biosciences (NASDAQ:RCUS) announced an update from the fourth interim analysis of Phase 2 ARC-7 study in patients…
Gilead And Arcus Biosciences Announce Positive Update On Joint TIGIT Program From Interim Analysis of ARC-7 Study In Non-Small Cell Lung Cancer; Shares Spike Higher
– Fourth Interim Analysis Shows Continued Clinically Meaningful Differentiation Across All Efficacy Measures, Including PFS, in Both Domvanalimab-Containing Arms Compared to the Anti-PD-1 Zimberelimab Monotherapy
SVB Leerink Maintains Outperform on Arcus Biosciences, Lowers Price Target to $38
SVB Leerink analyst Daina Graybosch maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and lowers the price target from $40 to $38.
ON Semiconductor, Global Payments And Other Big Losers From Monday
U.S. stocks closed lower on Monday, with the Dow Jones dropping more than 100 points. Here is the list of some big stocks recording losses in the previous session.
Analysts Turn Bullish On Gilead After Q3 Earnings Surpass Expectations
Thursday, Gilead Sciences Inc (NASDAQ:GILD) reported Q3 revenue decreased 5% Y/Y to $7.04 billion, which beat average analyst estimates of $6.12…